The weekly injection, approved by the FDA in June, works by decreasing a person’s appetite and has been shown in clinical trials to help people lose an average of 15 percent of their body weight.
“Demand is strong. It’s of course unfortunate that we can’t help all patients,” Lars Fruergaard Jørgensen, Novo Nordisk’s CEO, said Nov. 3, according to Bloomberg.
He said Novo Nordisk is working through supply constraints and should be able to meet demand by early next year.
Analysts expect Wegovy to become a blockbuster drug next year and reach annual revenues of $3.2 billion in 2024, Bloomberg reported. The drug costs $1,000 to $1,500 per month.
An estimated 1 billion people worldwide are expected to be considered obese by 2025, Bloomberg reported.
Read the full article here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
